How do we know if we are living in a miracle moment. And if we are, what should we do. On July 27th, 2023, I received an email asking me if I wanted to be interviewed by Oprah Winfrey for a special she was doing about obesity.It is an incredible time to be a physician scientist specializing in obesity. After decades of struggling to improve the health of our patients, we finally have effective new medications for this disease. Until 2023, my research focused on the care of obesity was only published in acad ...

SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to its Board of Directors (the "Board"), effective July 22, 2025. Ms. Averill has also been appointed to serve as a member of the Audit Committee. She succeeds Bihua Chen, who has stepped down from the Board after more than four years of dedicated service. "Julianne i ...

Core Insights - WeightWatchers has successfully completed its strategic reorganization, enhancing its financial flexibility and accelerating its transformation with key leadership appointments and product milestones [1][2] - The company is launching an integrated women's health initiative focused on perimenopause and menopause, combining medical, nutritional, lifestyle, and community support [1][6] Leadership Changes - Dr. Kim Boyd has been appointed as Chief Medical Officer to lead the clinical strategy and program innovation, focusing on integrating emerging science into holistic solutions for members [3][4] - Uta Knablein has been appointed as Chief Product Officer to drive product strategy across the expanding weight health platform, bringing over two decades of experience in digital transformation and consumer-centric product development [9] Women's Health Initiative - WeightWatchers will introduce a new program later this year to support women through perimenopause, menopause, and postmenopause, offering tailored nutritional and behavioral strategies along with specialized clinical care [6][7] - The initiative aims to address a significant gap in healthcare for menopause, leveraging the company's existing strengths to deliver sustainable weight loss results [7][8] Board of Directors - A new Board of Directors has been established to guide the company through its next growth phase, including experienced leaders from various sectors such as healthcare and consumer platforms [11][12] - Notable appointments include Mike Mason, former President of Eli Lilly's Diabetes and Obesity business, who will contribute to the company's strategic direction in obesity care [12][13] Company Overview - WeightWatchers is recognized as the global leader in science-backed weight management, with over 60 years of experience and a holistic approach that combines clinical interventions, medications, and community support [16]

Core Insights - Hims & Hers Health (HIMS) and Novo Nordisk (NVO) have announced a partnership to enhance obesity care through telehealth, allowing access to Novo Nordisk's FDA-approved weight loss drug Wegovy on Hims & Hers' platform [1][7][15] Company Performance - Hims & Hers stock has surged over 30% in 2025 following the partnership announcement, while Novo Nordisk's stock has declined more than 20% year to date [2] - Hims & Hers has experienced a remarkable stock performance, with shares soaring over 600% in the last three years, compared to Novo Nordisk's 15% increase [3] Sales and Earnings Projections - Hims & Hers total sales are projected to increase by 58% in fiscal 2025 to $2.33 billion, with further growth of 21% expected in FY26 to $2.84 billion [4] - Annual earnings for Hims & Hers are anticipated to rise over 160% this year to $0.72 per share, with FY26 EPS forecasted to increase by 48% to $1.07 [5] EPS Estimates - Hims & Hers has seen positive earnings estimate revisions, with FY25 and FY26 EPS estimates increasing by 14% and 12% respectively in the last 30 days [11] - Novo Nordisk's FY25 EPS estimates have slightly decreased over the last quarter but increased by 1% in the last month, while FY26 estimates have risen by 2% [13] Market Outlook - Novo Nordisk's sales are expected to grow by 18% in FY25 and another 15% in FY26, reaching $57.1 billion, with EPS growth projected at 17% this year and 22% in FY26 to $4.71 per share [8]

Novo Nordisk (NVO) is expected to beat estimates when it reports its first-quarter 2025 results before the opening bell on May 7, 2025. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $11.33 billion, while the same for earnings is pinned at 91 cents per share. (See the Zacks Earnings Calendar to stay ahead of market-making news.)In the past 30 days, the Zacks Consensus Estimate for Novo Nordisk’s 2025 earnings per share (EPS) declined from $3.88 to $3.81. Durin ...